Especially, we discovered ESYT3 as a tumor suppressor and a novel radioimmune response sensitizer for LUAD, which can activate cGAS-STING-dependent DNA damage response through directly interacting with STING, acting as a potential treatment target for improving LUAD prognosis. Here, ESYT3 is linked to neoplasm.